# ILKCAN COKGOR, M.D.

50 Red Hill Ave. San Anselmo, CA 94960
cokgor@gmail.com • 415.456.8180 (o) 415.302.7901 (m)


*General Neurology, Stroke Director at Marin Health Medical Center*

Well-respected and disciplined Neurologist with fellowship in Neuro-oncology at Duke University. Held faculty position at Duke University and UC Davis before moving to private practice. Board certified in Neurology, licensed in California since 2000. Extensive experience in both hospital and clinical settings, volunteered at community clinics.

Areas of Expertise

- Stroke
- Movement disorders
- Botox
- Dementia
- Neuromuscular disorders
- NCS/EMG
- Multiple Sclerosis
- Migraine/Headache disorders
- EEG

## Professional Experience

**Neurology Clinic of Marin (own practice)** (2001 - Present)

Solo practitioner, Neurology, focusing on stroke, migraine, dementia and movement disorders

I built my private practice from ground up and have a patient population of 5,000. I have experienced staff taking calls from patients and doing prior authorizations on a timely basis. I work full time every day and offer Botox, EMG/NCS in my clinic. I am on call for Marin medical health center 50% of the time every month and I follow up my outpatients in the hospital when they get admitted. I offer tele health services and accept every insurance.

**Marin Medical Health Center** (2018 to present)

Stroke Director, Neurology

We implemented cutting edge TNK protocols, CT perfusion scanners and collaborated with UCSF for large vessel occlusion patient transfers. MMHC is now a comprehensive stroke facility. I play a role in updating all stroke protocols.

**University of California at Davis** (2001 to 2004)

Clinical Associate, Neuro-Oncology

I worked at department of Neurosurgery and treated their brain tumor patients, wrote and applied clinical trials and gave chemotherapies in conjunction with Department of Oncology.

**Marin Oncology Associates** (2000 to 2001)

Neuro-Oncology

I treated metastatic and primary brain tumor patients as well as neurological complications of oncology patients.

**Duke University Medical Center** (1998 to 2000)

Assistant Professor of Neurology, Neuro-Oncology

*…continued…*

# Ilkcan Cokgor, M.D.

I was the director of clinical trials of monoclonal antibodies in primary brain tumor patients. I ran a busy brain tumor clinic, involved in clinical research and gave lectures regarding my research.

## Education and Credentials

| | | |
|---|---|---|
| Hacettepe University<br>Ankara, Turkey | 1989 | Research Fellowship, Dept.<br>of Neurosurgery |
| Uludag University | 1990 | Residency, Neurosurgery, Turkey |
| University of British Columbia<br>Vancouver, Canada | 1991-1993 | Ph.D. Program in Neuroscience<br>Department of Ophthalmology |
| Meridia Huron Hospital<br>East Cleveland, Ohio | 1993-1994 | Internship, Internal Medicine |
| Duke University Medical Center<br>Durham, North Carolina | 1994-1997 | Residency, Neurology |
| Duke University Medical Center<br>Durham, North Carolina | 1997-1998 | Fellowship, Neuro-Oncology<br>Neurology |
| Duke University Medical Center<br>Durham, North Carolina | 1998-1999 | Associate<br>Neuro-Oncology, Neurology |
| Duke University Medical Center<br>Durham, North Carolina | 1999-2000 | Assistant Professor of Neurology<br>Neuro-Oncology, Neurology |
| University of California<br>at Davis Medical Center<br>Department of Neuro-surgery | 2000-2004 | Clinical Associate<br>Neuro-Oncology, Neurosurgery |

## Professional Licensure and Specialty Certifications

| | |
|---|---|
| American Board of Psychiatry and Neurology | 1998-Present |
| Licensed in California, Neurology | 2000-Present |
| Licensed in North Carolina, Neurology | 1997-2001 |
| Member of American Academy of Neurology | 1994-Present |

## Awards and Recognitions

Graduate Research Assistantship, University of British Columbia, 1991

# Ilkcan Cokgor, M.D.

Research Scholarship, The Network of Centres of Excellence (NCE) on Neural Regeneration and Functional Recovery, 1993

Annual American Academy of Neurology Meeting Scholarship for Residents, 1996

Platinum and Gold Stroke Medical Center awards 2018-Present

## Research & Publications

1. Bigner, D.D., Brown, M.T., Friedman, A.H., Coleman, R.E., Akabani, G., Friedman, H.S., Thorstad, W.L., McLendon, R.E., Bigner, S.H., Zhao, X-G., Pegram, C.N., Wikstrand, C.J., Herndon, J.E., II, Vick, N.A., Paleologos, N., **Cokgor, I.**, Provenzale, J.M., and Zalutsky, M.R.: Iodine-131-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J. Clin. Oncol. 16:2202-2212, 1998.

2. Friedman, H.S., Kokkinakis, D.M., Pluda, J., Friedman, A.H., **Cokgor, I.**, Haglund, M.M., Ashley, D.M., Rich, J.N., Dolan, M.E., Pegg, A.E., Moschel, R.C., McLendon, R.E., Kerby, T., Herndon, J.E., Bigner, D.D., and Schold, S.C. Jr.: Phase I trial of $O^6$-benzylguanine for patients undergoing surgery for malignant glioma. J. Clin. Oncol. 16:3570-3575, 1998.
3. **Cokgor, I.**, Friedman, A.H., and Friedman, H.S.: Pediatric Update: Gliomas. Eur. J. Cancer 34:1910-1918, 1998.
4. Friedman, H.S., McLendon, R.E., Kerby, T., Dugan, M., Bigner, S.H., Henry, A.J., Ashley, D.M., Krischer, J., Lovell, S., Rasheed, K., Marchev, F., Seman, A.J., **Cokgor, I.**, Rich, J., Stewart, E.S., Colvin, O.M., Provenzale, J.M., Bigner, D.D., Haglund, M.M., Friedman, A.H., and Modrich, P.L.: DNA mismatch repair and $O^6$-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J. Clin. Oncol. 16:3851-3857, 1998.

5. **Cokgor, I.**, Rozear, M., and Morganlander, J.C.: Seizures and Creutzfeldt-Jacob Disease: A case report and series review. North Carolina Medical Journal 60:108-109, 1999.

6. **Cokgor, I.,** Friedman, H.S., and Friedman, A.H.: Chemotherapy for adults with malignant glioma. Cancer Invest. 17:264-272, 1999.

7. Akabani, G., Reist, C.J., **Cokgor, I.,** Friedman, A.H., Coleman, R.E., Zhao, X-G., Bigner, D.D., and Zalutsky, M.R.: Dosimetry of $^{131}$I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. J. Nucl. Med. 40:631-638, 1999.

8. Friedman, H.S., Petros, W.P., Friedman, A.H., Schaaf, L.J., Kerby, T., Lawyer, J., Parry, M., Houghton, P.J., Lovell, S., Rasheed, K., Cloughsey, T., Stewart, E.S., Colvin. O.M., Provenzale, J.M., McLendon, R.E., Bigner, D.D., **Cokgor, I.**, Haglund, M., Rich, J., Ashley, D., Elfring, G.L., and Miller, L.L.: Irinotecan (CPT-11) therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 17:1516-1525, 1999.

9. Friedman, H.S., Kerby, T., Fields, S., Zilisch, J.E., Graden, D., McLendon, R.E., Houghton, P.J., Arbuck, S., **Cokgor, I.**, Friedman, A.H., Ashley, D.M., Lovell, S., Rasheed, K., Longee, D.C., Bottom, K.S., Stewart, E.S., Colvin, O.M.,

Provenzale, J.M., Bigner, D.D., Rich, J.N., Haglund, M., and Scurlock-Jones, M.: Topotecan treatment of adults with primary malignant glioma. Cancer 85:1160–1165, 1999.

10. **Cokgor, I.**, Akabani, G., Wikstrand, C., Zalutsky, M.R., Friedman, H.S., Friedman, A.H., and Bigner, D.D.: Radiolabeled monoclonal antibodies for malignant glioma: an improvement over current therapy? The Medscape, 2000, Vol. 3, No: 3 at Medscape.com

11. Friedman, H.S., Ashley, D.M., Longee, D.C., Bottom, K.S., Moghrabi, A., Kerby, T., Provenzale, J., Stewart, E.S., Rasheed, K., Lovell, S., Hammond, C., Parry, M., Crane, J., **Cokgor, I.**, Rich, J., Brown, M., McLendon, R., and Friedman, A.H.: Treatment of adults with progressive oligodendroglioma with carboplatin. 1999.
12. Akabani, G., **Cokgor, I.,** Coleman, R.E., Trotter, D.G., Wong, T., Herndon, J.E. II, DeLong, D., McLendon, R.E., Zhao, X-G., Pegram, C.N., Bigner, D.D. and Zalutsky, M.R.: Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int. J. Radiat. Oncol. Biol. Phys.1999

13. **Cokgor, I.,** Akabani, G., Kuan, C.-T., Friedman, H.S., Friedman, A.H., Coleman, R.E., McLendon, R.E., Bigner, S.H., Zhao, X.-G., Garcia-Turner, A.M., Pegram, C.N., Wikstrand, C.J., Herndon II, J.E., Provenzale, J.M., Zalutsky, M.R., and Bigner, D.D.: Phase I trial results of 131I-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. 2000

14. **Cokgor, I.,** M.D., Gamal Akabani, Ph.D., Henry S. Friedman, M.D., Allan H. Friedman, M.D., Michael R. Zalutsky, Ph.D., Lee M.Zehngebot, M.D., James M. Provenzale, M.D., Cynthia D. Guy, M.D., Carol J. Wikstrand, Ph.D., Darell D. Bigner, M.D., Ph.D: Long term response in a patient with neoplastic meningitis secondary to melanoma treated with 131I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab); Cancer, Volume 91, Issue 9, 2001. Pages: 1809-1813

15. David A. Reardon, Gamal Akabani, R. Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, II, **Ilkcan Cokgor**, Roger E. McLendon, Charles N. Pegram, James M. Provenzale, Jennifer A. Quinn, Jeremy Rich, Lorna V. Regalado, John H. Sampson, Timothy D. Shafman, Carol J. Wikstrand, Terrence Z. Wong, Michael R. Zalutsky, Xiao-Guang Zhao, and Darell D. Bigner: Phase II Trial Results of Murine 131I-Labeled Anti-Tenascin Monoclonal Antibody 81C6 Administered into Surgically Created Resection Cavities of Patients with Newly Diagnosed Malignant Gliomas; Journal of Clinical Oncology, Volume 20, No:5, March 2002. Pages: 1389-1397

**CHAPTERS**

1. **Cokgor, I.**: Spinal cord compression and its management. Neurology Staff Handbook, 1999.

2. Wikstrand, C.J., **Cokgor, I.,** Sampson, J.H., and Bigner, D.D.: Monoclonal antibody therapy of human gliomas: current status and future approaches.. Cancer and Metastasis Reviews, 1999.

# Ilkcan Cokgor, M.D.

**SELECTED ABSTRACTS AND ORAL PRESENTATIONS**

1. **Cokgor, I.**, Dyck, R.H., and Cynader, M.S.: Localization of Nerve Growth Factor Binding Sites in Developing Kitten Visual Cortex. Society for Neuroscience Abstracts 17(1), 365, 1991.

2. **Cokgor, I.**, Cynader, M.S.: Developmental Expression of Fibroblast Growth Factor (bFGF) in the Cat Visual Cortex. Society of Neuroscience Abstracts 18(2), 1308, 1992.

3. **Cokgor, I.**, Akabani, G., Brown, M.T., Friedman, A.H., Coleman, R.E., Friedman, H.S., Thorstad, W.L., McLendon, R.E., Bigner, S.H., Zhao, X.-G., Pegram, C.N., Wikstrand, C.J., Herndon, J.E., Vick, N.A., Paleologos, N., Zalutsky, M.R., and Bigner, D.D.: Phase 1 trial results of patients with recurrent brain tumors and prior external beam therapy treated with $^{131}$I-labeled anti-tenascin monoclonal antibody 81C6 via surgically-created resection cavities. Therapeutic Antibody Technology, 1997.

4. Bigner, D.D., Brown, M., Friedman, A., Coleman, R.E., Akabani, G., Friedman, H.S., Thorstad, W., McLendon, R.E., Bigner, S.H., Zhao, X.-G., Pegram, C.N., Wikstrand, C.J., Herndon, J., Vick, N.A., Paleologos, N., **Cokgor, I.**, and Zalutsky, M.R.: Research of a Phase 1 trial of patients with recurrent brain tumors and prior radiation treatment with I$^{131}$-labeled anti-tenascin monoclonal antibody 81C6 via surgically created resection cavities. 12$^{th}$ International Conference on Brain Tumor Research and Therapy, 1997.

5. Petros, W.P., Schaaf, L., **Cokgor, I.** et al: Reduced systemic exposure to irinotecan and its active metabolite (SN-38) in patients with glioma receiving concurrent anti-convulsants and corticosteroids. American College of Clinical Pharmacology, 1997.

6. **Cokgor, I.**, Akabani, G., Brown, M.T., Friedman, A.H., Coleman, R.E., Friedman, H.S., Thorstad, W.L., McLendon, R.E., Bigner, S.H., Zhao, X.-G., Pegram, C.N., Wikstrand, C.J., Herndon, J.E., Vick, N.A., Paleologos, N., Zalutsky, M.R., and Bigner, D.D.: Results of a phase I trial of patients with recurrent brain tumors and prior radiation therapy treated with $^{131}$I-labeled anti-tenascin monoclonal antibody 81C6 via surgically created resection cavities. Neurology 50, A354, 1998.

7. **Cokgor, I.** et al.: Phase I trial of patients with recurrent brain tumors and prior radiation therapy treated with $^{131}$I-labeled anti-tenascin monoclonal antibody 81C6 via surgically created resection cavity. American Society of Clinical Oncology, May 1998.

8. Friedman, H.S., Dugan, M., Kerby, T., Henry, A.J., Ashley, D., Lovell, S., Rasheed, K., **Cokgor, I.**, Friedman, A.H., and Modrich, P.: DNA mismatch repair analysis and response to Temodal® in newly diagnosed malignant glioma. Presentation: American Society of Clinical Oncology, 1998. Proc. Am. Soc. Clin. Oncol. 17:378a, 1998.

9. Colvin, O.M., **Cokgor, I.**, Ashley, D.M., Kerby, T., Arbuck, S., Malczyn, J., Miller, L., Cloughesy, T., Houghton, P.J., Cokgor, I., Rich, J., Friedman, A.H., and Friedman, H.S.: Irinotecan treatment of adults with recurrent or progressive malignant glioma. Presentation: American Society of Clinical Oncology, 1998. Proc. Am. Soc. Clin. Oncol. 17:387a, 1998.

10. Sampson, J.H., **Cokgor, I.**, Akabani, G., Friedman, A., Coleman, E., Friedman, H., McLendon, R., Zhou, X., Bigner, S., Pegram, C., Wikstrand, C., Vick, N., Paleologos, N., Zalutsky, M., and Bigner, D.: Radiolabeled anti-tenascin monoclonal antibody in recurrent malignant brain tumors. Presentation: American Association of Cancer Research, 1998. Proc. Amer. Assoc. Cancer Res. 39:324, 1998.

11. Friedman, A.H., Friedman, H.S., Kokkinakis, D.M., Pluda, J., **Cokgor, I.**, Ashley, D.M., McLendon, R.E., Kerby, T., Bigner, D.D., and Schold, S.C., Jr.,: Phase I trial of $O^6$-benzylguanine for patients undergoing surgery for malignant glioma. Presentation: Third Annual European Association for Neuro-Oncology Congress, September 13-16, 1998, Versailles, France. J. Neurooncol. 39:152, 1998.

12. **Cokgor, I.**, Kerby, T., Houghton, P.J., Rich, J., Malczyn, J., Miller, L., Colvin, O.M., Friedman, A.H., Friedman, H.S.: Treatment of malignant glioma with irinotecan (CPT-11) ± BCNU. Presentation: Third Annual European Association for Neuro-Oncology Congress, September 13-16, Versailles, France, 1998.

13. **Cokgor, I.**, Akabani, G., Friedman, H.S., et al: Results of a phase I trial of patients with recurrent brain tumors and prior radiation therapy treated with 131 labeled anti-tenascin monoclonal antibody 81C6. Presentation: Third Annual European Association for Neuro-Oncology Congress September 13-16, Versailles, France, 1998.

14. Zalutsky, M.R., Akabani, G., **Cokgor, I.**, Friedman, H.S., Coleman, R.E., Friedman, A.H., McLendon, R.E., Reist, C.J., Pegram, C.N., Zhao, X.-G., and Bigner, D.D.: Phase I trial of astatine-211 labeling human/mouse chimeric anti-tenascin antibody administered into malignant brain tumor resection cavities. Presentation: Third annual meeting of the Society for Neuro-Oncology, November 13-15, 1998, San Francisco. Neuro-Oncology, 1:235a, 1999.

15. Akabani, G., Reist, C.J., **Cokgor, I.**, Friedman, A.H., Friedman, H.S., Zhao, X.-G., Coleman, R.E., Bigner, D.D., and Zalutsky M.R.: Radiation dosimetry for patients with recurrent brain tumors treated with $^{131}$I- and $^{211}$At-labeled anti-tenascin monoclonal antibody 81C6. Presentation: Third annual meeting of the Society for Neuro-Oncology, November 13-15, 1998, San Francisco. Neuro-Oncology, 1:3a, 1999.

16. Friedman, H.S., Kokkinakis, D.M., Pluda, J., Friedman, A.H., **Cokgor, I.,** Halund, M.M., Ashley , D.M., Rich, J.N., Dolan, E., Pegg, A.E., Moschel, R.M., McLendon, R.E., Kerby, T., Herndon, J.E., Bigner, D.D., and Schold, S.C., Jr.: Phase I trial of $O^6$-benzylguanine for patients undergoing surgery for malignant glioma. Presentation: Third annual meeting of the Society for Neuro-Oncology, November 13-15, 1998, San Francisco. Neuro-Oncology, 1:63a, 1999.

17. Sampson, J.H., Friedman, A.H., Coleman, R.E., Akabani, G., Friedman, H.S., Vick, N.A., Paleologos, N., **Cokgor, I.**, Zalutsky, M.R., and Bigner, D.D.: Results of dose finding study for compartmental delivery of radiolabeled anti-tenascin monoclonal antibody 81C6 in patients with recurrent malignant gliomas with prior whole brain radiation. Presentation: Third annual meeting of the Society for Neuro-Oncology, November 13-15, 1998, San Francisco. Neuro-Oncology, 1:194a, 1999.

18. Provenzale, J.M., Rodriguez, D., Coleman, R.E., Friedman, H.S., Akabani, G., **Cokgor, I.**, et al.: Worsening MR and PET findings do not necessarily indicate tumor progression in patients with resected primary brain tumors undergoing treatment with intracavitary iodine-$^{131}$-labeled anti-tenascin monoclonal antibody. Presentation: Radiological Society of North America, 1998. Radiology 209(P), Abstract #256.

19. **Cokgor, I.**, Akabani, G., Brown, M.T., Friedman, A.H., Coleman, R.E., Friedman, H.S., Thorstad, W.L., McLendon, R.E., Bigner, S.H., Zhao, X.-G., Pegram, C.N., Wikstrand, C.J., Herndon, J.E., Vick, N.A., Paleologos, N., Zalutsky, M.R., and Bigner, D.D.: Phase I trial of patients with recurrent brain tumors and prior radiation therapy treated with $^{131}$I-labeled anti-tenascin monoclonal antibody 81C6 via surgically-created resection cavities. Presentation: American Society of Clinical Oncology, 1998. Proc. Am. Soc. Clin. Oncol. 17:380a, 1998.

20. **Cokgor, I.**, Akabani, G., Friedman, A.H., Coleman, R.E., Zalutsky, M.R., McLendon, R.E., Bigner, S.H., Xiao-Guang, Z., Pegram, C.N., Wikstrand, C.J., Herndon J.E., III, Provenzale, J.M., Friedman, H.S. and Bigner, D.D.: Phase I trial of newly diagnosed brain tumor patients treated with $^{131}$I-labeled anti-tenascin MAb 81C6 via surgically created resection cavities (SCRC). Presentation: American Academy of Neurology, April 1999.

21. Colvin, O., **Cokgor, I.,** Kerby, T., Lawless, A., Rich, J., Stewart, E., Rasheed, K., Affronti, M., Tourt-Uhlig, S., Provenzale, J., McLendon, R., Bigner, D., Zilisch, J., Graden, D., Fields, S.Z., Friedman, A., and Friedman, H.: Phase I trial of topotecan plus BCNU in malignant glioma. Presentation: American Society of Clinical Oncology, May 15-18, 1999, Atlanta, GA. Proc. Am. Soc. Clin. Oncol. 18:150a, 1999.

22. Friedman, H., **Cokgor, I.,** Kerby, T., Lawless, A., Rich, E., Stewart, E., Rasheed, K., Affronti, M., Tourt-Uhlig, S., Provenzale, J., McLendon, R., Colvin, O., Bigner, D., Malczyn, J., Friedman, A., and Miller, L.: Phase I trial of CPT-11 plus BCNU in malignant glioma. Presentation: American Society of Clinical Oncology, May 15-18, 1999, Atlanta, GA. Proc. Am. Soc. Clin. Oncol. 18:150a, 1999.

23. Friedman, A., **Cokgor, I.,** Kerby, T., Edwards, S., Rich, J., Stewart, E., McLendon, R., Affronti, M., Rasheed, K., Provenzale, J., Colvin, O., Bigner, D., Zaknoen, S., Fraass, U., Dugan, M., and Friedman, H.: Phase II treatment of anaplastic oligodendroglioma and low grade glioma with Temodal®. Presentation: American Society of Clinical Oncology, May 15-18, 1999, Atlanta, GA. Proc. Am. Soc. Clin. Oncol. 18:150a, 1999.

24. Cohen, L., Friedman, H., **Cokgor, I.,** Kerby, T., Rich, J., Stewart, E., McLendon, R., Provenzale, J., Malczyn, J., Miller, L., Zaknoen, S., Fraass, U., Dugan, M., Colvin, O., Bigner, D., Friedman, A., and Friedman, H.: Phase I trials of gliadel™ plus CPT-11 or Temodal® (temozolomide). Presentation: American Society of Clinical Oncology, May 15-18, 1999, Atlanta, GA. Proc. Am. Soc. Clin. Oncol. 18:149a, 1999.

25. **Cokgor, I.,** Akabani, G., Friedman, A.H., Coleman, R.E., Zalutsky, M.R., McLendon, R.E., Bigner, S.H., Xiao-Guang, Z., Pegram, C.N., Wikstrand, C.J., Herndon, J.E. III, Provenzale, J.M., Friedman, H.S., and Bigner, D.D.: The treatment of newly diagnosed brain tumor patients with $I^{131}$ anti-tenascin monoclonal antibody 81C6 *via* surgically created resection cavities: results of a Phase I trial. Presentation: American Society of Clinical Oncology, May 15-18, 1999, Atlanta, GA. Proc. Am. Soc. Clin. Oncol. 18:143a, 1999.

26. Provenzale, J.M., Rodriguez, D., Petrella, J.R., Wong, J., Wong, T., Friedman, H.S., Friedman, A., Akabani, G., **Cokgor, I.,** McLendon, R.E., Bigner, D.D., and Coleman, R.E.: Test characteristics of MR and FDG PET in discriminating tumor progression from radiation necrosis after $^{131}$I-labeled monoclonal antibody treatment. Presentation: American Society of Neuroradiology, May 22-28, 1999, San Diego, CA. Am. J. Neuroradiol., in press, 1999.

27. Friedman, H.S., McLendon, R.E., Dolan, M.E., Pegg, A.E., Moschel, R.C., Colvin, O.M., **Cokgor, I.,** Friedman, A.H., Schold, S.C., Bigner, D.D., and Modrich, P.L.: The biology of sensitivity and resistance to the molecule (temozolomide). Presentation: American Association for Cancer Research, April 10-14, 1999, Philadelphia, PA. Proc. Am. Assoc. Cancer Res. 40:754, 1999.

28. Sampson, J.H., **Cokgor, I**., Akabani, G., Friedman, A.H., Coleman, R.E., Zalutsky, M.R., McLendon, R.E., Bigner, S.H., Xiao-Guang, A., Pegram. C.N., Wikstrand, C.J., Herndon, J.E., III, Provenzale, J.M., Friedman, H.S., and Bigner, D.D.: Phase I/II trial of newly diagnosed brain tumor patients treated with $^{131}$I-anti-tenascin MAb 81C6 *via* surgically created resection cavities. Presentation: American Association for Cancer Research, April 10-14, 1999, Philadelphia, PA. Proc. Am. Assoc. Cancer Res. 40:572, 1999.

29. Petros, W.P., Schaaf, L.J., **Cokgor, I.,** Kerby, T.A., Colvin, O.M., Friedman, A.H., Knuth, D.W., Elfring, G.L., and Friedman, H.S.: Reduced systemic exposure to irinotecan and its active metabolite (SN-38) in patients with glioma receiving concurrent anticonvulsants and corticosteroids. Presentation: American College of Clinical Pharmacology. J. Pharmacother., in press, 1999.

30. **Cokgor, I.**, Akabani, G., Friedman, A.H., Coleman, R.E., Zalutsky, M.R., McLendon, R.E., Bigner, S.H., Xiao-Guang, Z., Pegram, C.N., Wikstrand, C.J., Herndon, J.E. III, Provenzale, J.M., Friedman, H.S., and Bigner, D.D.: Newly diagnosed malignant glioma patients treated with $^{131}$I/anti-tenascin monoclonal antibody (MAb) 81C6 via surgically created resection cavities: results of a phase I trial. The 13$^{th}$ International Conference on Brain Tumor Research and Therapy. Neuro-Onc. 1:158-O, 1999.

31. Akabani, G., **Cokgor, I.**, Gonzalez Trotter, D., Xiao-Guan, Z., Garcia-Turner, A., DeLong, D., Herndon, J.E. III, Pegram, C.N., McLendon, R.E., Coleman, R.E., Bigner, D.D. and Zalutsky, M.R.: Dosimetry and dose-response relationships for iodine-131-labeled anti-tenascin monoclonal antibody 81C6 in newly diagnosed patients with malignant gliomas. The 13$^{th}$ International Conference on Brain Tumor Research and Therapy. Neuro-Onc. 1:201, 1999.

32. Zalutsky, M.R., Akabani, G., **Cokgor, I.,** Friedman, H.S., Coleman, R.E., Friedman, A.H., McLendon, R.E., Zhao, X.-G., Alston, K.L., and Bigner, D.D.: Dose escalation study of compartmental delivery of astatine-211 labeled human/mouse chimeric anti-tenascin antibody in patients with recurrent malignant gliomas. Presentation: The 13th International Conference on Brain Tumor Research and Therapy. Neuro-Onc. 1:178, 1999.

33. Friedman, H.S., **Cokgor, I.**, Kerby, T., Albergo, G., Rich, J., Stewart, E., Rasheed, K., Affronti, M., Tourt-Uhlig, S., Provenzale, J., McLendon, R., Colvin, O., Bigner, D., Malczyn, J., Friedman, A., and Miller, L.: Phase I trial of CPT-11 plus BCNU in malignant glioma. Presentation: The Society of Neuro-Oncology, November 18-21, 1999, Scottsdale, AZ. Neuro-Onc. 1:71a, 1999.

34. Friedman, H.S., **Cokgor, I**., Kerby, T., Edwards, S., Albergo, G., Tourt-Uhlig, S., Rich, J., Stewart, E., McLendon, R., Provenzale, J., Malczyn, J., Miller, L., Zaknoen, S., Fraass, U., Dugan, M., Colvin, O., Bigner, D., Friedman, A., and Cohen, L.: Phase I trials of Gliadel™ plus CPT-11 or Temodal→ (temozolomide). Presentation: The Society of Neuro-Oncology, November 18-21, 1999, Scottsdale, AZ. Neuro-Onc. 1::73a, 1999.

35. Friedman, H., **Cokgor, I.,** Kerby, T., Albergo, G., Rich, J., Stewart, E., Rasheed, K., Affronti, M., Tourt-Uhlig, S., Provenzale, J., McLendon, R., Bigner, D., Zilisch, J., Graden, D., Fields, S.Z., Colvin, O., Friedman, A.: Phase I trial of topotecan plus BCNU in malignant glioma. Presentation: The Society of Neuro-Oncology, November 18-21, 1999, Scottsdale, AZ. Neuro-Onc. 1:72a, 1999.

36. Friedman, A., **Cokgor, I.,** Kerby, T., Edwards, S., Rich, J., Stewart, E., McLendon, R., Affronti, M., Rasheed, K., Provenzale, J., Colvin, O., Bigner, D., Zaknoen, S., Fraass, U., Dugan, M., Friedman, H.: Phase II treatment of anaplastic oligodendroglioma and low grade glioma with Temodal→. Presentation: The Society of Neuro-Oncology, November 18-21, 1999, Scottsdale, AZ. Neuro-Onc. 1:70a, 1999.

37. Zalutsky, M.R., Akabani, G., **Cokgor, I.,** Friedman, H.S., Coleman, R.E., Friedman, A.H., McLendon, R.E., Zhao, X.-G., Alston, K.L., and Bigner, D.D.: Compartmental administered astatine-211 labeled chimeric anti-tenascin monoclonal antibody (mAB) therapy in recurrent malignant glioma patients: current status of a phase study. Presentation: The Society of Neuro-Oncology, November 18-21, 1999, Scottsdale, AZ. Neuro-Onc. 1:218a, 1999.

38. **Cokgor, I.**, Bigner, D.D., Brown, M., Friedman, A., Coleman, R.E., Akabani, G., Friedman, H.S., Thorstad, W., McLendon, R.E., Bigner, S.H., Zhao, X.-G., Pegram, C.N., Wikstrand, C.J., Herndon, J., Vick, N.A., Paleologos, N., and Zalutsky, M.R.: Results of a phase I trial in newly diagnosed malignant glioma patients treated with $^{131}$I anti-tenascin monoclonal antibody 81C6. The Society of Neuro-Oncology, November 18-21, 1999, Scottsdale, AZ. Neuro-Onc. 1:51a, 1999.

39. **Cokgor, I**, Kokkinakis, D.M., Pluda, J., Friedman, A.H., Haglund, M.M., Ashley, D.M., Rich, J.N., Dolan, M.E., Pegg, A.E., Moschel, R.M., McLendon, R.E., Kerby, T., Herndon, J.E., Bigner, D.D., Schold, S.C., Jr., and Friedman, H.S**.**: Phase I trial of $O^6$-benzylguanine plus BCNU for patients undergoing surgery for malignant glioma. The 124th

Annual Meeting of the American Neurological Association, October 10-13, 1999, Seattle, Washington, 68:176, 1999.

40. Zalutsky, M.R., **Cokgor, I.,** Akabani, G., Friedman, H.S., Coleman, R.E., Friedman, A.H., McLendon, R.E., Reist, C.J., Pegram, C.N., Zhao, X.G., and Bigner, D.D.: Phase I trial of alpha-particle-emitting astatine-211 labeled chimeric anti-tenascin antibody in recurrent malignant glioma patients. The 91st Annual Meeting of the American Association of Cancer Research, April 1-5, 2000, San Franciso, California, submitted, 1999.

41. Provenzale, J.M., Petrella, J.R., Holmes T.M., Cruz L.C., **Cokgor, I**., Friedman, H.S., McLendon, R.E: Evaluation of Cerebral Neoplasms Using Perfusion MR Imaging. American Society Neuroradiology, In Press, 2000.

42. Hinman, J.M., Provenzale, J.M., Akabani, G., Zalutsky, M.R., **Cokgor, I**., Friedman, H.S., Coleman, R.E., Bigner, D.D.: Patterns of Recurrent Tumor and Radiation Necrosis in $^{211}$Astatine-Labeled Monoclonal Antibody Therapy. AM Society of Neuroradiology, In Press, 2000.

43. Petrella, J.R., Luna, A., Provenzale, J.M., Holmes, T., McLendon R.E., **Cokgor**, **I**., Friedman, H.S.: Distinguishing Radiation Treatment Effects from Tumor Progression in Patients with Treated Cerebral Gliomas using Cerebral Blood Volume Mapping. AM Society of Neuroradiology, In Press, 2000.

44. **Cokgor, I.**, Akabani, G., Friedman, A., Coleman, R., Zalutsky, M., McLendon, R., Bigner, S., Xiao-Guang, Z., Pegram, C., Wikstrand, C., Herndon III, J., Provenzale, J., Friedman, H., Bigner, D.,: The Treatment of Recurrent Patients with Brain Tumors Treated with Iodine 131 Anti-tenascin Monoclonal Antibody 81C6 via Surgically Created Resected Cavities: The Results of a Phase II Trial. American Academy of Neurology, Volume 54 #7, Supplement 3, Page A33, May 2, 2000.

45. **Cokgor, I**., Akabani, G., Friedman, A., Coleman, R., Zalutsky, M., McLendon, R., Bigner, S., Xiao-Guang, Z., Pegram, C., Wikstrand, C., Herndon III, J., Provenzale, J., Friedman, H., Bigner, D.: Results of a Phase II Trial in the Treatment of Recurrent Patients with Brain Tumors Treated with Iodine 131 Anti-Tenascin Monoclonal Antibody 81c6 Via Surgically Created Resection Cavities. American Society of Clinical Oncology, Volume 19, Page 628, May 20-23, 2000.

46. **Cokgor, I**., Advances in Treatment of Primary Brain Tumors. UC Davis, Neurosurgery Grand Rounds, May 10, 2000.

47. **Cokgor, I**., Advances in Treatment of Primary Brain Tumors. Duke University Medical Center, Department of Neurosurgery Grand Rounds, May 31, 2000.

48. J. A. Quinn, **I. Cokgor**, J. Rich, H. Sands, S. Tourt-Uhlig, A. Garcia-Turner, B. Stewart, J. Sampson, A. Friedman, and H. Friedman: Phase I Trial of Intrathecal Busulfan for Patients With Neoplastic Meningitis; Duke University Medical Center, Durham, NC; and Supergen, San Ramon, CA; ASCO, Volume 19, Page 630, May 20-23, 2000

49. H. Friedman, **I. Cokgor,** S. Tourt-Uhlig, G. Albergo, J. Rich, J. Quinn, E. Stewart, K. Rasheed, M. Affronti, J. Provenzale, R. McLendon, O. Colvin, D. Bigner, R. Beason, J. Sampson, M. Haglund, A. Friedman, L. Miller: PHASE I TRIAL OF CPT-11 PLUS BCNU IN MALIGNANT GLIOMA. Duke University Medical Center; Pharmacia and Upjohn; ASCO, Volume 19, Page 654, May 20-23, 2000.

50. Friedman, **I. Cokgor,** S. Edwards, J. Rich, J. Quinn, E. Stewart, R. McLendon, M. Affronti, K. Rasheed, J. Provenzale, S. Tourt-Uhlig, J. Sampson, M. Haglund, O. Colvin, D. Bigner, S. Zaknoen, V. Stafford-Fox, H. Friedman: PHASE II TREATMENT OF ANAPLASTIC OLIGODENDROGLIOMA AND LOW GRADE GLIOMA WITH TEMODAR; Duke University Medical Center; and Schering-Plough Research Institute; ASCO, Volume 19, Page 662, May 20-23, 2000.

51. O. Colvin, **I. Cokgor**, S. Edwards, G. Albergo, S. Tourt-Uhlig, J. Rich, J. Quinn, E. Stewart, R. McLendon, J. Provenzale, J. Sampson, M. Haglund, R. Beason, L. Miller, S. Zaknoen, U. Fraass, M. Dugan, D. Bigner, V. Stafford-Fox, L. Cohen, A. Friedman, and H. Friedman: PHASE I TRIALS OF GLIADEL PLUS CPT-11 OR TEMODAR; Duke University Medical Center; Schering-Plough Research Institute; Pharmacia and Upjohn; Rhone-Poulenc Rorer.; Duke University Medical Center, Durham, NC; and Supergen, San Ramon, CA

52. H. Friedman, **I. Cokgor**, S. Tourt-Uhlig, G. Albergo, J. Rich, J. Quinn, E. Stewart, K. Rasheed, M. Affronti, J. Provenzale, R. McLendon, O. Colvin, D. Bigner, R. Beason, J. Sampson, M. Haglund, A. Friedman, L. Miller: PHASE I TRIAL OF CPT-11 PLUS BCNU IN MALIGNANT GLIOMA; Duke University Medical Center; Pharmacia and Upjohn.

53. Friedman, **I. Cokgor**, S. Edwards, J. Rich, J. Quinn, E. Stewart, R. McLendon, M. Affronti, K. Rasheed, J. Provenzale, S. Tourt-Uhlig, J. Sampson, M. Haglund, O. Colvin, D. Bigner, S. Zaknoen, V. Stafford-Fox, H. Friedman: PHASE II TREATMENT OF ANAPLASTIC OLIGODENDROGLIOMA AND LOW GRADE GLIOMA WITH TEMODAR; Duke University Medical Center; and Schering-Plough Research Institute.

54. O. Colvin, **I. Cokgor**, S. Edwards, G. Albergo, S. Tourt-Uhlig, J. Rich, J. Quinn, E. Stewart, R. McLendon, J. Provenzale, J. Sampson, M. Haglund, R. Beason, L. Miller, S. Zaknoen, U. Fraass, M. Dugan, D. Bigner, V. Stafford-Fox, L. Cohen, A. Friedman, and H. Friedman: PHASE I TRIALS OF GLIADEL PLUS CPT-11 OR TEMODAR; Duke University Medical Center; Schering-Plough Research Institute; Pharmacia and Upjohn; Rhone-Poulenc Rorer.

55. Akabani, G., **Cokgor, I**., Coleman, R.E., Trotter, D.G., Wong, T.Z., Friedman, H.S., Garcia-Turner, A., Herndon II, J.E., DeLong, D., McLendon, R.E., Zhao, X.-G., Pegram, C.H., Bigner, D.D., and Zalutsky, M.R.: Dosimetry and dose-response relationships in newly diagnosed patients treated with iodine 131I-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int. J. Radiat. Oncol. Biol. Phys 46:947-958, 2000.

56. Provenzale, J.M., Rodriguez, D., Petrella, J.R., Wong, J., Wong, T., Friedman, H.S., Friedman, A., Akabani, G., **Cokgor**, **I**., McLendon, R.E., Bigner, D.D., and Coleman, R.E.: Test characteristics of MR and FDG PET in discriminating tumor progression from radiation necrosis after 131I-labeled monoclonal antibody treatment.

Presentation: American Society of Neuroradiology, May 22-28, 1999, San Diego, CA. Am. J. Neuroradiol., in press, 2000.

57. Petros, W.P., Schaaf, L.J., **Cokgor**, **I**., Kerby, T.A., Colvin, O.M., Friedman, A.H., Knuth, D.W., Elfring, G.L., and Friedman, H.S.: Reduced systemic exposure to irinotecan and its active metabolite (SN-38) in patients with glioma receiving concurrent anticonvulsants and corticosteroids. Presentation: American College of Clinical Pharmacology. J. Pharmacother., in press, 2000.

58. Friedman, H.S., Pluda, J., Bigner, D.D., Pegg, A.E., Moschel, R.C., **Cokgor, I**., Rich, J., Friedman, A.H., and Dolan, M.E.: Phase I trial of *O*6-benzylguanine plus BCNU for patients with recurrent malignant glioma. Presentation: 91st Annual Meeting of the American Association of Cancer Research, April 1-5, 2000, San Francisco, CA. Proc. Amer. Assoc. Cancer Res. 41:397, 2000.

59. Zalutsky, M.R., **Cokgor, I**., Akabani, G., Friedman, H.S., Coleman, R.E., Friedman, A.H., McLendon, R.E., Reist, C.J., Pegram, C.N., Zhao, X.-G., and Bigner, D.D.: Phase I trial of alpha-particle-emitting astatine-211 labeled chimeric anti-tenascin antibody in recurrent malignant glioma patients. Presentation: 91st Annual Meeting of the American Association of Cancer Research, April 1-5, 2000, San Francisco, CA. Proc. Amer. Assoc. Cancer Res. 41:544, 2000.

60. Provenzale, J.M., Petrella, J.R., Holmes, T.M., Cruz, L.C.H., Jr., **Cokgor, I**., Friedman, H.S., and McLendon, R.E.: Evaluation of cerebral neoplasms using perfusion MR imaging. Presentation: 38th Annual Meeting of the American Society of Neuroradiology, April 2-8, 2000, Atlanta, GA. Submitted, 2000.

61. Petrella, J.R., Luna, A., Provenzale, J.M., Holmes, T., McLendon, R.E., **Cokgor, I.,** and Friedman, H.S.: Distinguishing radiation treatment effects from tumor progression in patients with treated cerebral gliomas using cerebral blood volume mapping. Presentation: 38th Annual Meeting of the American Society of Neuroradiology, April 2-8, 2000, Atlanta, GA. Submitted, 2000.

62. **Cokgor, I**., Akabani, G., Friedman, A., Coleman, R., Zalutsky, M., McLendon, R., Bigner, S., Xiao-Guang, Z., Pegram, C., Wikstrand, C., Herndon, J., III, Provenzale, J., Friedman, H., and Bigner, D.: Initial results in a Phase II clinical trial of recurrent brain tumor patients treated with Iodine-131 anti-tenascin monoclonal antibody 81C6 via surgically created resection cavities. Presentation: 36th Annual Meeting of the American Society of Clinical Oncology, May 20-23, 2000, New Orleans, LA. Submitted, 2000.

63. Bigner, D., Akabani, A., Friedman, A., Coleman, R., Zalutsky, M., McLendon, R., Bigner, S., Xiao-Guang, Z., Pegram, C., Wikstrand, C., Herndon, III, J., Provenzale, J., Friedman, H., and **Cokgor, I**.: Phase II clinical trial results of recurrent brain tumor patients treated with iodine-131 anti-tenascin monoclonal antibody 81C6. Presentation: Fourth Congress of the European Association of Neuro-Oncology, June 3-6, 2000, Copenhagen, Denmark. Submitted, 2000.

64. Friedman, H., Colvin, O., **Cokgor, I.,** Edwards, S., Albergo, G., Tourt-Uhlig, S., Rich, J., Quinn, J., Stewart, E., McLendon, R., Provenzale, J., Sampson, J., Haglund, M., Beason, R., Miller, L., Zaknoen, S., Fraass U., Dugan, M.,

Bigner, D., Stafford-Fox, V., Cohen, L., and Friedman, A.: Phase I trials of gliadel plus CPT-11 or Temodar. Presentation: Fourth Congress of the European Association of Neuro-Oncology, June 3-6, 2000, Copenhagen, Denmark. Submitted, 2000.

65. Hinman, J.M., Provenzale, J.M., Akabani, G., Zalutsky, M.R., **Cokgor, I**., Friedman, H.S., Coleman, R.E., and Bigner, D.D.: Patterns of recurrent tumor and radiation necrosis in 211Astatine-labeled monoclonal antibody therapy. Submitted, 2000.

66. Reardon, D., Akabani, G., Friedman, A., Friedman, H., Herndon, J., **Cokgor, I**., McLendon, R., Quinn, J., Rich, J., Regalado, L., Sampson, J., Shafman, T., Wong, T., Zalutsky, M., Bigner, D.: Outcome of newly diagnosed patients with high-grade glioma treated with Iodine-131 Murine Anti-Tenascin Monoclonal Antibody 81C6 via surgically created resection cavities in a phase-II trial. American Society of Clinical Oncology, Volume 20, Part 1 of 2, Page 66a #212, May 12-15, 2001

67. Shafman, T., Friedman, H., Friedman, A., Akabani, J., **Cokgor, I**., Herndon, J.,McLendon, R., Quinn, J., Reardon, J., Rich, J., Regalado, L., Sampson, J., Wong, T., Zalutsky, M., Bigner, D.: Update of a phase-II trial of Iodine-131 labeled Anti-Tenascin Monoclonal Antibody treatment of patients with recurrent brain. American Society of Clinical Oncology, Volume 20, Part 1 of 2, Page 67a #263, May 12-15, 2001

**EDITORIALS, POSITION AND BACKGROUND PAPERS, AND INVITED LECTURES**

1. **Cokgor, I.** "Prion Diseases," Duke University Medical Center, Durham, NC, 17 January 1996.

2. **Cokgor, I.** "Prion Diseases," Meridia Huron Hospital, Cleveland, OH, 18 March 1996.

3. **Cokgor, I.** "Current Treatment on Migraine," Maria Parham Hospital, Henderson, NC, 23 April 1997.

4. **Cokgor, I.** "New Developments in Monoclonal Antibody in Primary Brain Tumors". Physical and Occupational Therapy, Duke University Medical Center, Durham, NC, February 1998.

5. **Cokgor, I.** "Primary Brain Tumors", School of Physician Assistants, Duke University Medical Center, Durham, NC, May 1998.

6. **Cokgor, I.** "Monoclonal Antibody Therapies for Primary Brain Tumors", Hopital Sainte-Justine, Montreal, Canada, 26 February 1999.

7. **Cokgor, I.** "Embryonal Cell Carcinoma" Grand Rounds, Duke University Medical Center, 31 March 1999.

8. **Cokgor, I.** "Multidisciplinary Care of Brain Tumors" Grand Rounds, Duke University Medical Center, 5 May 1999.

9. **Cokgor, I.** "Monoclonal Antibody Therapy", Cape Fear Valley Health System, Fayetteville, NC, 11 May 1999.

10. **Cokgor, I.** "New Developments in the Treatment of Multiple Sclerosis", Marin General Hospital, Greenbrae, CA, September 2001

11. **Cokgor, I.** "Educational Conference in Multiple Sclerosis", Biogen Meeting for MS Support Group, Terra Linda, CA, September 2001

12. **Cokgor, I.** "Current Treatments in Management of Migraine Headaches", Novato Community Hospital, Novato, CA, November 2001

13. **Cokgor, I.** "Advances in Treatment of Parkinson's Disease", PD Support Group, Mill Valley, CA, December 2001

14. **Cokgor, I.** "Brain Tumor Protocols", UC Davis Medical Center, Sacramento, CA, January 2002